New indications for exenatide therapy of type 2 diabetes mellitus

Código QR

New indications for exenatide therapy of type 2 diabetes mellitus

Obesity associated with the enhanced risk of cardiovascular disorders plays a key role in the evolvement and progression of type 2 diabetes mellitus(DM2). Incretin mimetics are the sole class of hypoglycemic agents that not only effectively correct hyperglycemia but also reduce body weight. Exenatid...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Olga Konstantinovna Vikulova, Marina Vladimirovna Shestakova
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2010
Materias:	type 2 diabetes mellitus obesity incretin mimetics exenatide byetta Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/966c47654fdf45d8a1986ff7d62d681c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Pharmalogical effects and results of clinical trials of the first incretinomimetic exenatide
por: Alexander Sergeevich Ametov, et al.
Publicado: (2011)

Ion- and osmoregulating renal functions in patients with type 2 diabetes mellitus
por: Evgeniya Vladimirovna Balbotkina, et al.
Publicado: (2016)

New prospects in the treatment of diabetes mellitus
por: Minara Shamkhalovna Shamkhalova, et al.
Publicado: (2012)

Glibenclamide therapy: pros and cons
por: Olga Konstantinovna Vikulova, et al.
Publicado: (2011)

Inсretin-based therapy in patients with type 2 diabetes and chronic kidney disease
por: Minara Shamkhalovna Shamkhalova, et al.
Publicado: (2012)

National register of diabetes mellitus in Russian Federation.
por: Ivan Ivanovich Dedov, et al.
Publicado: (2015)

The results of open observational trial DIAMOND
por: Marina Vladimirovna Shestakova, et al.
Publicado: (2011)

Type 2 diabetes mellitus: time to change the concept
por: Shmuel Levit, et al.
Publicado: (2013)

Obesity - a risk factor of renal pathology in patients with type 2 diabetes mellitus
por: Svetlana Alekseevna Savel'eva, et al.
Publicado: (2010)

Ileal transposition in surgical treatment for type 2 diabetes mellitus
por: Oleg Viktorovich Kornyushin, et al.
Publicado: (2015)

Renal allograft nephropathy in patient with type 1 diabetes mellitus
por: Ekaterina Vladimirovna Ivannikova, et al.
Publicado: (2012)

Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus
por: Seewoodhary J, et al.
Publicado: (2010)

Pathogenetic significance of single nucleotide polymorphisms in the gastric inhibitory polypeptide receptor gene for the development of carbohydrate metabolism disorders in obesity
por: Daria S. Skuratovskaia, et al.
Publicado: (2016)

Epidemiology of diabetes mellitus in Russian Federation: clinical and statistical report according to the federal diabetes registry
por: Ivan Ivanovich Dedov, et al.
Publicado: (2017)

Vildagliptin and its role in the treatment of diabetes mellitus
por: Yury Shavkatovich Khalimov
Publicado: (2010)

Pre-clinical markers for diagnosis of diabetic nephropathy in patients with type 1 diabetes mellitus
por: Nadezhda Olegovna Lebedeva, et al.
Publicado: (2012)

Diabetes and obesity. The role of agonists glucagon-like peptide-1 of in the treatment of type 2 diabetes
por: Nina A. Petunina, et al.
Publicado: (2018)

New glance at pathogenesis of type 2 diabetes mellitus: incretin and antiincretin systems.
por: Ekaterina Alekseevna Shestakova
Publicado: (2011)

Comments on the Consensus statement of the American Diabetes Association and the European Association for the Studyof Diabetes on the medical management of hyperglycemia in type 2 diabetes
por: Ivan Ivanovich Dedov, et al.
Publicado: (2009)

The 3d World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension, Prague, 13-16 May 2010
por: Olga Konstantinovna Vikulova, et al.
Publicado: (2010)

Intensification of glucose-lowering treatment in patients with diabetes mellitus type 2 on insulin therapy: Perspectives of dapagliflozin
por: Olga Yuryevna Sukhareva, et al.
Publicado: (2016)

Glucagon and alpha-cells as a novel therapeutic target in the management of diabetes mellitus
por: Nina Alexandrovna Petunina, et al.
Publicado: (2013)

The dynamics of the main epidemiological indicators among living in Moscow patients with diabetes mellitus (2013–2018)
por: Mikhail B. Antsiferov, et al.
Publicado: (2020)

First GLP-1 analog liraglutide: the result of clinical trails on efficacy
por: Alexander Sergeevich Ametov, et al.
Publicado: (2011)

Commentary on prevention of cardiovascular complications in diabetes mellitus as novel inidicationfor Diabeton MR
por: Olga Konstantinovna Vikulova
Publicado: (2012)

The role of human glucagon-like peptide-1 analog in therapy of type 2 dianetes mellitus
por: Marina Vladimirovna Shestakova
Publicado: (2010)

Diabetes mellitus and chronic kidney disease: achievements, unresolved problems, and prospects for therapy
por: Marina Vladimirovna Shestakova, et al.
Publicado: (2011)

Efficacy and safety of metformin-sitagliptin combination for the treatment of patients with diabetes mellitus and obesity
por: Alexander Sergeevich Ametov, et al.
Publicado: (2010)

Prevalence of renal lesions in patients with type 1 and 2 diabetes mellitus in the Russian Federation
por: Oksana Vladimirovna Maslova, et al.
Publicado: (2009)

Experience with sitagliptin (the first DPP-4 inhibitor) application to the treatment of type 2 diabetes mellitus in the Russian Federation:Results of the DIA-DA observation program
por: Marina Vladimirovna Shestakova
Publicado: (2010)

Possibilities of metabolic surgery for the treatment of type 2 diabetes mellitus in patients with grade 1 alimentary obesity
por: Vladimir V. Salukhov, et al.
Publicado: (2018)

The role of the tissue renin-angiotensin-aldosterone system in the development of metabolic syndrome, diabetes mellitus and itsvascular complications
por: Marina Vladimirovna Shestakova
Publicado: (2010)

Clinical implementetion of vildagliptin: data from recent studies comparing incretin-based medications
por: Elena Valer'evna Biryukova
Publicado: (2014)

Priority areas in management of diabetes mellitus type 1 & 2 (following 47th EASD Annual Meeting)
por: Ivona Renata Yarek-Martynova, et al.
Publicado: (2011)

Standards of Medical Care in Diabetes-2009 (American Diabetes Association): executive summary
por: Olga Konstantinovna Vikulova
Publicado: (2009)

Prospects for the use of fecal microbiota transplantation in obese patients with Type 2 Diabetes Mellitus for weight loss and improvement of insulin sensitivity
por: E. V. Pokrovskaya, et al.
Publicado: (2021)

Cognitive impairment in patients with type 2 diabetes mellitus: prevalence, pathogenetic mechanisms, the effect of antidiabetic drugs
por: Olga D. Ostroumova, et al.
Publicado: (2018)

Diabetes mellitus type 2: a new indication for hypercortisolism screening?
por: Natalya Ivanovna Volkova, et al.
Publicado: (2012)

Pharmacoeconomic assessment of type 2 diabetes mellitus care on the base of Endocrinology Research Centre, Moscow
por: Ivan Ivanovich Dedov, et al.
Publicado: (2012)

Russian multicentre type 2 diabetes screening program in patients with cardiovascular disease
por: Marina Vladimirovna Shestakova, et al.
Publicado: (2016)